Drug intelligence / Profile preview

Putong Granules

Development stage: Preclinical
Lead developer: Beijing Yingkerei Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

Putong Granules (蒲通颗粒) is an innovative traditional Chinese medicine (TCM) candidate developed by Beijing Yingkerei Pharmaceutical Technology. Formulated as oral granules, the drug is primarily being developed for the treatment of hyperuricemia and gout. As a TCM product, it likely utilizes a combination of herbal extracts designed to regulate uric acid metabolism and provide anti-inflammatory effects. It is currently in the IND-enabling (preclinical) stage of development, where it is undergoing the necessary safety and efficacy evaluations to support an Investigational New Drug application.

Other names: 蒲通颗粒Putong Granules

Beyond the preview

Go deeper on Putong Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Putong Granules.

Explore the full profile